Pathology & Oncology Research

, Volume 16, Issue 4, pp 583–587

Correlation Between Survival and Number of Mobilized CD34+ Cells in Patients with Multiple Myeloma or Waldenström Macroglobulinemia

  • Kazuhiko Kakihana
  • Kazuteru Ohashi
  • Hideki Akiyama
  • Hisashi Sakamaki
Article

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation is the established treatment for symptomatic multiple myeloma (MM) or Waldenström macroglobulinemia (WM). We retrospectively analyzed the impact of mobilized CD34+ cell number on clinical outcomes in patients with MM or WM who underwent autologous stem cell transplantation in our hospital from 1997 to 2007. A total of 39 patients were identified. All patients received peripheral stem cell support after a conditioning regimen. We defined patients with collection of a large number (≥ 8 × 106/kg) of CD34+ cells as super mobilizers (SM), and all others as normal mobilizers (NM). Although hematological engraftment was earlier in the SM group, overall survival did not differ significantly between groups (P = 0.392). Likewise, no significant differences were seen in progression-free survival (P = 0.201) or survival after relapse (P = 0.330). In conclusion, our retrospective study could not find any correlation between survival and number of mobilized CD34+ cells, in contrast to previously reported results.

Keywords

Mobilized CD34+ cell number Multiple myeloma Waldenström macroglobulinemia Autologous stem cell transplantation 

References

  1. 1.
    Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91–97CrossRefPubMedGoogle Scholar
  2. 2.
    Barlogie B, Jagannath S, Vesole DH et al (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789–793PubMedGoogle Scholar
  3. 3.
    Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883CrossRefPubMedGoogle Scholar
  4. 4.
    Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233CrossRefPubMedGoogle Scholar
  5. 5.
    Stockerl-Goldstein KE, Reddy SA, Horning SF et al (2000) Favorable treatment outcome in non-Hodgkin’s lymphoma patients with “poor” mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 6:506–512CrossRefPubMedGoogle Scholar
  6. 6.
    Hiwase DK, Hiwase S, Bailey M et al (2008) Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 14:116–124CrossRefPubMedGoogle Scholar
  7. 7.
    Bolwell BJ, Pohlman B, Rybicki L et al (2007) Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 40:437–441CrossRefPubMedGoogle Scholar
  8. 8.
    Wang S, Nademanee A, Qian D et al (2007) Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Transfusion 47:2207–2216CrossRefPubMedGoogle Scholar
  9. 9.
    Galimberti S, Morabito F, Guerrini F et al (2003) Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 120:405–412CrossRefPubMedGoogle Scholar
  10. 10.
    Gordan LN, Sugrue MW, Lynch JW et al (2003) Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 44:815–820CrossRefPubMedGoogle Scholar
  11. 11.
    O’Shea D, Giles C, Terpos E et al (2006) Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 37:731–737CrossRefPubMedGoogle Scholar
  12. 12.
    Krejci M, Buchler T, Hajek R et al (2005) Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 35:159–164CrossRefPubMedGoogle Scholar
  13. 13.
    Wahlin A, Eriksson M, Hultdin M (2004) Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol 73:263–268CrossRefPubMedGoogle Scholar
  14. 14.
    Krejci M, Hajek R, Buchler T et al (2007) Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients. Neoplasma 54:143–148PubMedGoogle Scholar
  15. 15.
    Dean R, Masci P, Pohlman B et al (2005) Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival. Bone Marrow Transplant 36:1049–1052CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2009

Authors and Affiliations

  • Kazuhiko Kakihana
    • 1
  • Kazuteru Ohashi
    • 1
  • Hideki Akiyama
    • 1
  • Hisashi Sakamaki
    • 1
  1. 1.Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease CenterKomagome HospitalBunkyo-kuJapan

Personalised recommendations